<--- Back to Details
First PageDocument Content
Microbiology / Pneumococcal vaccine / Pneumococcal polysaccharide vaccine / Zostavax / Merck & Co. / Immunogenicity / Varicella zoster virus / Streptococcus pneumoniae / Vaccines / Medicine / Biology
Microbiology
Pneumococcal vaccine
Pneumococcal polysaccharide vaccine
Zostavax
Merck & Co.
Immunogenicity
Varicella zoster virus
Streptococcus pneumoniae
Vaccines
Medicine
Biology

Summary Basis for Regulatory Action Template

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 66,01 KB

Share Document on Facebook

Similar Documents

Universal detection reagent for immunogenicity assays EBF – Young Scientist Symposium 2015 Elli Oksanen

DocID: 1v3Ky - View Document

Induction of Tolerance to Immunotoxins Using Nanoparticle Delivery of Rapamycin Ronit Mazor and Ira Pastan Immunogenicity summit October 2016

DocID: 1uGDJ - View Document

Medicine / Cancer / Clinical medicine / Papillomavirus / Vaccines / RTT / Infectious causes of cancer / Immunology / Virus-like particle / HPV vaccines / Immunogenicity / Human papillomavirus infection

The UNM Interdisciplinary HPV Prevention Center

DocID: 1rtWC - View Document

Medicine / Biology / Clinical medicine / Biotechnology / Immunology / ActoBiotics / Autoimmune diseases / Bacteriology / Biopharmaceutical / Immunogenicity / Mucositis / Human microbiota

Overview ActoBiotics® Platform: A Novel Class of Oral Biotherapeutics

DocID: 1rtnN - View Document

Pharmaceutical sciences / Pharmacology / Business / Pharmaceutical industry / Pharmacy / Biotechnology / European Federation of Pharmaceutical Industries and Associations / Immunogenicity / Drug discovery / Novartis / Biopharmaceutical / Sanofi

ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for

DocID: 1rlyu - View Document